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Unbiased analysis of pancreatic cancer
radiation resistance reveals cholesterol
biosynthesis as a novel target for
radiosensitisation
J J Souchek1,7, M J Baine1,7, C Lin*,2, S Rachagani3, S Gupta3, S Kaur3, K Lester3, D Zheng2, S Chen4, L Smith5,
A Lazenby6, S L Johansson6, M Jain1,3 and S K Batra*,1,3
1
Fred & Pamela Buffet Cancer Center, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical
Center, Omaha, NE, USA; 2Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA;
3
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA; 4Department of
Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA; 5Department of Biostatistics, University of
Nebraska Medical Center, Omaha, NE, USA and 6Department of Pathology and Microbiology, University of Nebraska Medical
Center, Omaha, NE, USA

Background: Despite its promise as a highly useful therapy for pancreatic cancer (PC), the addition of external beam radiation therapy
to PC treatment has shown varying success in clinical trials. Understanding PC radioresistance and discovery of methods to sensitise PC
to radiation will increase patient survival and improve quality of life. In this study, we identified PC radioresistance-associated pathways
using global, unbiased techniques.
Methods: Radioresistant cells were generated by sequential irradiation and recovery, and global genome cDNA microarray analysis was
performed to identify differentially expressed genes in radiosensitive and radioresistant cells. Ingenuity pathway analysis was performed
to discover cellular pathways and functions associated with differential radioresponse and identify potential small-molecule inhibitors for
radiosensitisation. The expression of FDPS, one of the most differentially expressed genes, was determined in human PC tissues by IHC
and the impact of its pharmacological inhibition with zoledronic acid (ZOL, Zometa) on radiosensitivity was determined by colonyforming assays. The radiosensitising effect of Zol in vivo was determined using allograft transplantation mouse model.
Results: Microarray analysis indicated that 11 genes (FDPS, ACAT2, AG2, CLDN7, DHCR7, ELFN2, FASN, SC4MOL, SIX6, SLC12A2, and
SQLE) were consistently associated with radioresistance in the cell lines, a majority of which are involved in cholesterol biosynthesis. We
demonstrated that knockdown of farnesyl diphosphate synthase (FDPS), a branchpoint enzyme of the cholesterol synthesis pathway,
radiosensitised PC cells. FDPS was significantly overexpressed in human PC tumour tissues compared with healthy pancreas samples.
Also, pharmacologic inhibition of FDPS by ZOL radiosensitised PC cell lines, with a radiation enhancement ratio between 1.26 and 1.5.
Further, ZOL treatment resulted in radiosensitisation of PC tumours in an allograft mouse model.
Conclusions: Unbiased pathway analysis of radioresistance allowed for the discovery of novel pathways associated with resistance to
ionising radiation in PC. Specifically, our analysis indicates the importance of the cholesterol synthesis pathway in PC
radioresistance. Further, a novel radiosensitiser, ZOL, showed promising results and warrants further study into the universality of
these findings in PC, as well as the true potential of this drug as a clinical radiosensitiser.
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Pancreatic cancer (PC) is the fourth leading cause of cancer death
in the United States and has a 5-year survival rate of 6% (Siegel
et al, 2013). Patients with PC are usually diagnosed late in the
cancer’s progression, and therefore only 15–20% of patients are
eligible for curative-intent surgery. For patients diagnosed with
resectable or locally advanced disease, accounting for B40% of PC
patients, external beam radiation therapy (EBRT) is considered a
staple of therapy to either help prevent local failure or shrink the
tumour to the point of surgical resectability, respectively (Callery
et al, 2009; Hazard, 2009; Ryan and Mamon, 2009). Clinical trials
that have tested the ability of radiation to prolong progression-free
survival, increase overall survival, or improve quality of life in PC
patients, either alone or in combination with chemotherapy, have
shown mixed results (reviewed in Hazard (2009); Goodman and
Hajj (2013)). Further, only 20% of pancreatic primary tumours
show any significant response to radiation (Roldan et al, 1988;
Hazard, 2009).
This lack of clinical efficacy of PC irradiation, combined with
the substantial benefit that efficacious PC EBRT could provide,
mandates exploration of methods to overcome radiation resistance
in PC. Successful PC radiosensitisation could provide significant
benefit to patients diagnosed with resectable disease, as an
estimated 21% suffer solely from local failure post resection,
whereas an additional 20% fail both locally and distantly (Oettle
et al, 2007; Asiyanbola et al, 2009). To understand how to
overcome PC’s radioresistance and offer potential methods for
therapeutic radiosensitisation, the mechanisms underlying the lack
of radiation-induced cytotoxicity in PC must be elucidated.
The molecular pathways contributing to apparent resistance to
ionising radiation (IR) in PC remain poorly understood (Brunner
et al, 2005; Kimple et al, 2010; Fokas et al, 2012; Engelke et al,
2013). We employed a novel in vitro model of PC radiation
resistance to determine the global transcriptional differences
between radiosensitive and radioresistant PC cells. Several genes
were identified and validated, including many in the cholesterol
synthesis pathway, whose differential expressions significantly
correlated with in vitro PC radioresponse. Further, through these
methods, a putative radiosensitiser for PC was tested, zoledronic
acid (ZOL, Zometa, Novartis, East Hanover, NJ, USA), currently
used clinically for non-IR-related purposes. Finally, tumourspecific EBRT was performed using a linear accelerator for
treatment of a subcutaneous allograft model of PC, testing whether
ZOL could radiosensitise in vivo.
MATERIALS AND METHODS

Cell culture and materials. The human PC cell lines Panc-1 and
BxPC3 were obtained from the American Type Culture Collection
(Manassas, VA, USA). The L3.6pl human PC cell line was a kind
gift from Dr Michel Ouellette (UNMC). The mouse PC cell line
UN-KPC-961 was established in our laboratory from a primary
tumour generated in a spontaneous mouse model of PC, the LSLKrasG12D/ þ ;LSL-Trp53R172H/ þ ;Pdx-1-Cre (KPC) mouse model
(Torres et al, 2013). Cell lines were cultured per established lab
protocol (Singh et al, 2004). ZOL was purchased from Sigma (St
Louis, MO, USA) and was dissolved in sterile water. Clinical grade
ZOL (4 mg per 5 ml concentrate) was received from the oncology
pharmacy (Nebraska Medical Center, Omaha, NE, USA).
In vitro irradiation. In vitro irradiation was accomplished via a
linear accelerator in the Department of Radiation Oncology at
UNMC. Briefly, cells in exponential growth phase were plated at
40% confluence 24 h before irradiation. Flasks were placed on
10 cm of solid water (phantom material used for radiation beam
calibration) positioned in the centre of the 40 cm  40 cm radiation
field and irradiated with 6 MV X-rays at a rate of 2.73 Gy min ÿ 1
1140
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from the posterior direction, with the media being 100 cm from the
X-ray target. The dose to the media was verified with MOSFET
detectors (Best Medical Canada, Ottawa, ON, Canada).
Analysis of radiosensitivity of PC cell lines. Cellular radioresponse was determined by colony survival assay (CSA) using
standard protocol (Boothman et al, 1987). On the day of staining,
cells were washed, fixed in MeOH, and stained using 0.4% crystal
violet in 25% MeOH. Colonies containing 450 cells were counted
for each well and the number of colonies corresponding to each
radiation dose averaged. Surviving fraction at each dose was
determined by the formula (number of surviving colonies in
dose X)/(number of cells seeded for dose X  (average colonies
arising from the non-irradiated cells (0 Gy)/number of nonirradiated cells seeded)) (Kimple et al, 2010). Log (surviving
fraction) was plotted against dose for each condition. The linear
quadratic model (Y ¼ e^-[a*X þ b*X2]) was fit to the clonogenic
survival curve for each condition, where the parameters a and b
were calculated according to the method of Fertil (Fertil et al,
1984). The survival curve and linear quadratic fit were plotted
using GraphPad Prism (GraphPad Software Inc., La Jolla, CA,
USA) according to a least-squares fit, weighted to minimise the
relative distances squared as described previously (Kimple et al,
2010). The mean inactivation dose (equal to the area under the
survival curve) was also calculated according to the method of
Fertil (Fertil et al, 1984).
The radiation enhancement ratio (ER) was calculated as the
ratio of the mean inactivation dose under control conditions
divided by the mean inactivation dose of experimental conditions
(that is, another cell line, or siRNA or drug treatment), as described
previously (Morgan et al, 2008). A value significantly 41 indicates
radiosensitisation.
Generation of radioresistant PC cell lines. Selection for radiation-resistant subpopulations within parental PC cell lines was
attempted originally for both Panc-1 and BxPC3, chosen due to
their primary tumour origins as well as their poorly and
moderately differentiated status, respectively. Radioselection was
also performed in the L3.6pl cell line (derived from COLO 357,
which was established from a lymph node metastasis and has welldifferentiated status) for validation of results. Cells were subjected
to 2 Gray (Gy) radiation daily for 2 weeks, taking weekends off
(giving a total of 10 fractions). Throughout the irradiation process
and recovery time, cells were kept at 40–70% confluency to ensure
potential for exponential growth. After completion of the second
week of radiation, cells were maintained in media containing 10%
FBS, being washed and re-fed daily for the first 7 days and then
every third day thereafter. Radioselected radioresistance was
verified by comparing the radiosensitivity of the radiation-selected
cells (after a recovery period) with their respective parental cell
lines by CSA as described above.
RNA extraction and cDNA synthesis from PC cell lines. Total
RNA was extracted using the Qiagen RNAeasy RNA isolation kit
(Qiagen, Valencia, CA, USA). RNA was converted to cDNA using
2 mg of total RNA, oligo(dT)18 primer, and the SuperScript II
Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA).
Global gene expression analysis. Global genome microarray
analysis was performed by the UNMC microarray core facility.
Phalanx whole-genome cDNA microarray platforms were used
containing 30 275 features probing for B22 000 unique genes. To
ensure valid comparison across cell lines, all samples were
normalised against a universal human reference (Stratagene, Cat:
740000, Cedar Creek, TX, USA).
Discovery of radioresistance-associated pathways. Radioresistanceassociated pathways were determined by comparative gene
expression analysis of radioresistant cell line (Panc-1RR) with that
www.bjcancer.com | DOI:10.1038/bjc.2014.385
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of parental cell line exhibiting relative radiosensitivity (Panc-1). On
completion of unbiased discovery of radioresistance-associated
gene differential expression, ingenuity pathway analysis was
performed to identify pathways and cellular functions most
implicated in our radioresistance model, as well as to determine
potential targets for radiosensitisation.
Quantitative real-time PCR validation of microarray transcriptional
analysis. After analysis of microarray results for radioresistanceassociated differential expression, altered transcription of 12
selected genes associated with PC radioresistance was validated
using quantitative real-time PCR (qRT-PCR) using SYBR greenbased chemistry. qRT-PCR was performed using 1 ml of a 1 : 5
dilution of first-strand cDNA using the SYBR Premix Ex Taq kit
(Takara Bio, Madison, WI, USA) and specific primers (sequence in
Supplementary Table 4) on a Roche Light Cycler 480 system
(Roche Diagnostics, Mannheim, Germany). Fold change in gene
expression was determined by the delta-delta CT method as
described previously (Baine et al, 2011).
RNA interference and transient transfection. Farnesyl diphosphate synthase (FDPS) siRNA pool of three target-specific
19–25 nt siRNAs was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA) (sc-75011). For transient transfection,
recipient cells were seeded in a six-well plate 24 h before
transfection. Following serum starvation for 4 h, the cells were
transfected using Lipofectamine 2000 reagent (Invitrogen) according to manufacturer’s protocol. Four hours following transfections,
the cells were replenished with serum-containing media and
protein was isolated from the cells 48 h post transfection.
Whole-cell lysate preparation. Cells were rinsed with PBS and
then lysed on culture dishes using RIPA buffer containing protease
and phosphatase inhibitors (Moniaux et al, 2004) and stored at
ÿ 201C. Thawed samples were passed through a 27-gauge needle and
syringe, and clarified by centrifugation at 14 000 r.p.m. at 4 1C for
20 min. Protein concentration in lysates was determined by the BioRad DC protein assay (Bio-Rad Laboratories, Hercules, CA, USA).
SDS–PAGE and western blot analysis. Equal amounts of protein
were separated on 12% SDS–polyacrylamide gels and blotted onto
polyvinylidene fluoride membranes (EMB Millipore, Billerica, MA,
USA) and developed per lab protocol (Andrianifahanana et al,
2005). Horseradish peroxidase-conjugated appropriate secondary
antibodies were diluted at 1 : 3000 in PBS and incubated for 1 h at
room temperature. After three washes in PBST, membranes were
developed using the Pierce ECL Western Blotting Substrate
(Thermo, Rockford, IL, USA) and blots were exposed to ECLsensitive film (MIDSCI, St Louis, MO, USA). The films were
digitally scanned, and figures were assembled using Microsoft
PowerPoint.
Immunohistochemistry. Tissue arrays comprised of normal
pancreas (from donors for pancreas transplant) and PC patient
samples were obtained from the Rapid Autopsy Program of the
University of Nebraska Medical Center (PI: Michael Hollingsworth, IRB# 091-01-FB). The tissues were stained with anti-FDPS
polyclonal antibody (ab38854, Abcam, Cambridge, MA, USA)
using an antibody dilution of 1 : 100. The immunostaining
technique was performed according to the standard laboratory
procedure (Moniaux et al, 2008). The FDPS staining was scored
by a pathologist using the criteria described in Supplementary
Methods. Representative photographs were taken under a Nikon
light microscope with a Q-capture Micropublisher 5.0 camera
(Leeds Precision Instruments, Minneapolis, MN, USA) by utilising
the Q-capture suite software package (QImaging, Surrey,
BC, Canada).
www.bjcancer.com | DOI:10.1038/bjc.2014.385
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Evaluation of pathway-directed pharmaceuticals for cell growth
inhibition and radiosensitisation. MTT assay was performed
with 10 nM–100 mM ZOL to evaluate toxicity. Subsequently, cell
lines were exposed to ZOL in conjunction with radiation and
assessed by colony forming assay as described above. Concentrations of 10 nM–10 mM of ZOL were used with radiation, as these
concentrations have been previously shown to inhibit pathways of
interest (Chen et al, 2002; Skerjanec et al, 2003; Almubarak et al,
2011). Cells were treated with ZOL either before and after radiation
or only after as indicated. Once cells were switched to media
containing 5% FBS, all media given to the cells was drug free.
Tumour implantation. All animal studies were performed under
an approved protocol by the University of Nebraska Medical
Center Institutional Animal Care and Use Committee (IACUC).
Subcutaneous tumour growth was evaluated with the UN-KPC-961
mouse PC cell line. Cells (5  106) suspended in 50 ml sterile PBS
were injected in two areas (one to be irradiated and one
unirradiated) in immune-competent mixed Sv129/C57BL/6 background mice on the right and left posterior lateral thorax caudal to
the axilla. Before implantation, mice were shaved at the site of
injection. Tumours were allowed to grow for 2 weeks before
randomisation. Tumour growth was monitored by measuring with
vernier calipers.
Radiation treatment planning. Planning CT scans (Sensation
Open; Siemens Healthcare, Eschborn, Germany) at a slice
thickness of 0.6 mm were performed in anaesthetised mice that
were implanted with pancreatic tumours. Before scanning, mice
were anaesthetised with xylazine/ketamine, and restrained in the
prone position. Gross tumour volume and the organs at risk such
as lung and spinal cord were contoured on axial CT slices of all
mice. A planning target volume expansion of 3 mm was used. The
iPlan (Brainlab AG, Feldkirchen, Germany) system was used by a
radiation oncologist and radiation physicist to generate 3D
conformal plans, providing a steep dose fall-off in normal tissue
away from the target to be irradiated (Supplementary Figure 1A).
The prescribed target dose was 35 Gy in 7 Gy daily fractions.
At least 95% of the prescribed dose encompassed 100% of the
planning target volume and at least 95% of the planning target
volume received 100% of the prescribed dose.
Radiation treatment. Radiation was delivered 2–3 days after
planning CT scans. One hour before irradiation, mice were
randomised to receive clinical grade ZOL (2 mg kg ÿ 1, 50 ml of a
4 mg per 5 ml solution for a 20 mg mouse; equivalent to a 10-mg
human dose calculated based on body surface area (Reagan-Shaw
et al, 2008)) or vehicle control by intraperitoneal injection.
The Novalis accelerator (Brainlab AG) was used to deliver
stereotactic radiation therapy. It incorporates stereotactic X-ray
capabilities for verifying target position (ExacTrac; Brainlab AG).
For soft-tissue targets, the system is designed to be used with radioopaque metal markers placed near the target. These markers can be
observed within the field of view of the X-ray localisation system at
the time of treatment. In detail, each mouse was anaesthetised and
restrained. A metal bb was placed on the tumour, and the locating
lasers in the x–y–z planes were placed directly on the bb/dot. Each
mouse was imaged with ExacTrac, and the mouse spine from the
ExacTrac image was superimposed onto the mouse spine from the
pre-treatment CT image (Supplementary Figure 1B shows before
and after ExacTrac). The couch position was adjusted accordingly.
Radiation treatment consisted of 35 Gy in 7 Gy daily fractions
delivered in 5 consecutive days with 3–5.5-mm multileaf
collimators (Novalis) and 6 MV photons with a dose rate of 480–
650 cGy min ÿ 1. No animal shielding was used, and no obvious
radiation toxicity was observed for subcutaneous tumour-targeted
radiation.
1141
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Measurement of treatment responses. Tumour volumes were
measured with calipers immediately before irradiation, and every
3–5 days after that. Tumour volume was calculated using the
formula: volume ¼ [length  (width^2)]/2.

after fractionated IR exposure (BxPC3-RR vs BxPC3), potentially
indicating that BxPC3 cells are either more homogenous in their
radiosensitivity or are incapable of becoming more radioresistant
(Figure 1D).

Histological analysis of radiated and ZOL-treated tumours.
Pathologic responses were scored by a pathologist. Necrosis was
measured in percentages at 10% increments. Fibrosis was measured
as described in Supplementary Methods.

Global expression analysis of PC cell lines. Microarray analysis
comparing global expression levels across cell lines revealed
notable differential expression profiles. A total of 54 genes were
found to be differentially expressed (Pp0.001), with fold
differences ranging from six-fold higher (FDPS) to five-fold lower
(LOC146481) in Panc-1RR as compared with Panc-1 parental cell
line (Supplementary Table 2). In contrast, only a few genes were
differentially expressed between BxPC3-RR and BxPC3, with
expression levels of only 8 genes found to be differentially
expressed between the two (Pp0.001), ranging from three-fold
higher (RASSF8) to four-fold lower (ASIP) in BxPC3-RR
(Supplementary Table 3).
Ingenuity pathway analysis of the differentially expressed genes
in Panc-1RR compared with Panc-1 indicates an array of cellular
functions that have a role in PC radioresistance, with the two most
associated cellular functions being lipid metabolism (P ¼ 2.66
E ÿ 08 to 6.83E ÿ 03) and small molecule biochemistry (that is,
synthesis of cholesterol and lipids; P ¼ 2.66E ÿ 08 to 6.83E ÿ 03).
Further, the canonical pathways exhibiting association with the
differentially expressed genes are those of the superpathway of
cholesterol biosynthesis (P ¼ 4.47E ÿ 11) (Figure 2A; the top eight
canonical pathways are involved in cholesterol/mevalonate
synthesis) and fatty acid biosynthesis (P ¼ 4.43E ÿ 3).

Statistical analysis. CSAs were performed no less than on two
separate dates for each cell line. Mean surviving colonies and s.e. were
calculated for each radiation dose and compared between cell lines.
Colony survival was considered a continuous variable and cell
lines were compared using two-tailed Student’s t-test with
P-values o0.05 being considered statistically significant. All CSA data
were analysed using the MedCalc version 9.3.0.0 software (MedCalc
Software bvba, Ostend, Belgium) and GraphPad Prism v.5.0.
Microarray analysis was accomplished through log2 transformation of all ratios followed by normalisation to ‘centre’ each array
using lowess smoother through BRB ArrayTools (Simon et al,
2007). Genes in which the percent of spots missing or filtered out
exceeded 50% were excluded. Genes whose expression differed by
at least 1.5-fold from the median in at least 20% of the samples
were retained, genes not meeting this criteria were excluded due to
low variability across the samples. Univariate analyses were
performed comparing each utilised cell line and cell line derivative
using a two-sample t-test using the random variance model.
P-values o0.001 were considered significant.
The non-parametric Wilcoxon rank sum test was used to
compare protein levels with radiation and chemotherapy status.
P-values o0.05 are statistically significant.
Response to treatment of tumour allografts was analysed with a
two-sample t-test, with P-value o0.05 considered significant.
RESULTS

qRT-PCR validation of radioresistance-associated genes. To
validate the results of the microarray analysis, 11 genes (FDPS,
ACAT2, AG2, CLDN7, DHCR7, ELFN2, FASN, SC4MOL,
SLC12A2, SQLE, and IDI1) found to be associated with PC
radioresistance were validated by qRT-PCR for differential
expression between Panc-1RR and Panc-1. From this analysis,
100% validation of microarray results was observed (Table 1).

Natural radiosensitivity varies across PC cell lines. CSAs of PC
cell lines revealed variation in their radiosensitivity (Figure 1A). Of
note, Panc-1 and BxPC3 revealed a significant difference in natural
radiosensitivity, with BxPC3 being more radioresistant than Panc-1
at doses of 3 Gy and above. These results indicate that an average of
1.6-fold radiation dose is required to produce equivalent cell death
in BxPC3 as in Panc-1. UN-KPC-961 was the most resistant line
used. The UN-KPC-961 cell line was derived and characterised in
our laboratory (Torres et al, 2013) from a primary tumour
developing in KPC (LSL-KrasG12D/ þ ;Trp53R172H/ þ ;Pdx-1-Cre)
genetically engineered mouse model of PC (Hingorani et al,
2005). It was observed that the immortalised human pancreatic
ductal epithelial cell line (HPDE) was highly sensitive to radiation,
with no colonies observed with a 2 Gy treatment and consequently,
could not be included in CSA analysis. Summary of cell line
mutations is presented in Supplementary Table 1.

Cell line expression of FDPS and siRNA knockdown for
radiosensitisation. As FDPS was the top differentially upregulated
gene in our microarray and because FDPS is a major branchpoint
enzyme of the cholesterol synthesis pathway, we further investigated its role in radioresistance. Western blotting revealed that
FDPS is expressed in all PC cell lines tested. Marginal increases in
FDPS protein expression could be seen in the Panc-1RR cells
compared with parental Panc-1, and in the recently induced
radiation-resistant subline L3.6pl-RR compared with parental
L3.6pl (Figure 2B).
To determine whether FDPS contributes to radiation resistance,
Panc-1RR cells were transfected with pooled siRNA to specifically
knockdown FDPS expression. Panc-1RR cells were successfully
transfected with either FDPS-specific siRNA or nonspecific control
scrambled siRNA, with knockdown of FDPS seen at 48 h after
transfection (Figure 2C). Radiosensitivity was examined at this 48 h
time point after transfection. Knockdown of FDPS increased
radiosensitivity, with an ER of 1.34 (Figure 2D).

Generation of radioresistant cell lines. For the generation of
radioresistant cell lines, cells were exposed to 10 fractions of 2 Gy
X-rays and then allowed to recover for 4 weeks (6–10 passages;
Figure 1B). After this recovery period, the Panc-1 subline that had
been exposed to 10 fractions of 2 Gy had a significant increase in
radioresistance as compared with parental Panc-1, with CSAs
indicating that Panc-1RR requires a 1.6-fold higher IR dose as
compared with parental Panc-1 to elicit equivalent cell death
(Figure 1C). This Panc-1 subline with confirmed induced radioresistance was subsequently referred to as Panc-1RR. Importantly,
this increased radioresistance was found to be stable, with similar
results obtained 6 and 18 passages after completion of the
fractionated IR regimen. No difference was observed in BxPC3

Immunohistochemistry of FDPS in PC patient samples. As
knockdown of FDPS resulted in radiosensitisation in PC cells, we
wanted to explore the presence of FDPS in human PC samples. PC
patient tissue array samples were obtained from the Rapid Autopsy
Program at the UNMC. Remarkably, staining with anti-FDPS
antibody revealed low expression of FDPS in normal pancreas
samples (n ¼ 8) from donors for pancreas transplant, but was
significantly overexpressed in 83% (24 out of 29) of primary
pancreatic adenocarcinoma patient samples (Figure 2E and F).
Tumour samples had a median composite score of 7.5 (range 0–12,
with 12 being the maximum score possible), while the mean
composite score of normal pancreas ranged from 0 to 1
(Figure 2G). No significant association between FDPS composite
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Figure 1. Response of PC cell lines to radiation and generation of radiation-resistant sublines. (A) Colony formation assays of PC cell lines exposed
to the indicated dose of radiation reveal a heterogeneous response. It was observed that the immortalised human pancreatic ductal epithelial cell line
(HPDE) was highly sensitive to radiation, with no colonies being observed with 2 Gy treatment (not shown). Cell line names are given with the mean
inactivation dose, ( QUOTE ), given in parentheses. Mean inactivation dose has units of Gy. (B) Schematic of the generation of radiation-resistant
sublines. Cell lines were exposed to 10 fractions of 2 Gy irradiation over a 2-week period and then allowed to recover. Subsequently, colony formation
assays were done following exposure to varying doses of radiation to compare the sensitivity between the parental and radioresistant sublines. (C)
Colony formation assay of Panc-1RR vs Panc-1. The Panc-1 subline exposed to fractionated radiation required 1.6-fold higher IR dose to elicit
equivalent cell death as the parental Panc-1, and was thus referred to as radioresistant, Panc-1RR. The mean inactivation dose, ( QUOTE ), is given in
parentheses. (D) Colony formation assay of BxPC3-RR vs BxPC3. No difference was observed between the naturally radioresistant parental line BxPC3
and the BxPC3 subline exposed to fractionated radiation (BxPC3-RR).

score and patient exposure to treatment with radiation or
chemotherapy was observed, as assessed by Wilcoxon rank sum
test (not shown).
ZOL radiosensitises PC cells. ZOL inhibits FDPS and thus, was
used for further study as a potential radiosensitiser. On analysis, it
was found that 10 mM ZOL acts as a potent radiosensitiser of Panc1RR, BxPC3, and BxPC3-RR cell lines, but not the naturally
sensitive Panc-1, with radiation ER of 1.26, 1.41, and 1.33 for
BxPC3, BxPC3-RR, and Panc-1RR, respectively (Figure 3). In MTT
assays, ZOL at 10 mM exhibited mild toxicity (data not shown);
however, this toxicity was accounted for in CSAs, as surviving
fraction is normalised to unirradiated control for each concentration of ZOL used. ZOL was also found to radiosensitise the
radioselected L3.6-RR cells and the naturally radioresistant UNKPC-961 cell line (Figure 3).
www.bjcancer.com | DOI:10.1038/bjc.2014.385

In vivo radiation treatment and ZOL radiosensitisation. To
determine whether ZOL treatment could radiosensitise PC cells
in vivo, UN-KPC-961 tumours were established subcutaneously
on the right (to be irradiated) and left (unirradiated control)
posterior lateral thorax of Sv129/C57BL/6 mixed background
mice. Each tumour-bearing mouse received a planning CT scan
and 3D conformal radiation treatment plan, generated within
2 days of the start of radiation treatment (Supplementary
Figure 1A). Mice bearing tumours of at least 100 mm3 were
randomly assigned to receive a single dose of either ZOL
(2 mg kg ÿ 1) or vehicle by intraperitoneal injection 1 h before
radiation. Tumours on the right lateral chest received five
fractions of 7 Gy (total 35 Gy) on 5 consecutive days. Even
without shielding of the mice, no obvious radiation toxicity
could be seen in mice receiving 35 Gy total dose targeted to
subcutaneous tumours. Tumour volume was measured with
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vernier calipers during the course of treatment to determine
response compared with the first day of radiation.
Unirradiated tumours in the mice that received a single
injection of ZOL were seen to shrink in the first week after

treatment, but then grew at the same rate as untreated tumours,
and by day 17 were not significantly different in mean percent
change in tumour volume. Tumours receiving radiation alone had
maximal tumour volume shrinkage by day 10, but in most mice it
exhibited increased size by day 17. Tumours receiving a single
injection of ZOL plus radiation had maximal tumour volume
shrinkage at day 17. Treatment response at day 17 was plotted and
compared by waterfall plot (Figure 4). Although 63% (5 out of 8) of
animals showed response with radiation alone, ZOL plus radiation
produced a response rate of 80% (8 out of 10). The mean percent
change in tumour volume for tumours receiving ZOL plus
radiation was not seen to be statistically significant (P ¼ 0.404)
compared with tumours receiving radiation alone. Histological
comparison of tumours revealed increased areas of fibrosis with
less tumour cell density in tumours receiving radiation, but no
significant differences were observed for fibrosis score or tumour
cell dropout in radiated tumours receiving ZOL compared with
radiation alone (Supplementary Figure 2).

Table 1. Validated genes differentially expressed in radioselected
Panc-1RR vs parental Panc-1 cell lines (fold change ratio shown)

Panc-1RR vs Panc-1
Gene name

qRT-PCR

Microarray

FDPS

7.14

5.93

ACAT2

2.49

3.03

AG2

1.87

2.59

CLDN7

0.07

0.49

DHCR7

1.15

2.96

ELFN2

0.01

0.34

FASN

1.97

2.62

SC4MOL

2.83

3.57

SLC12A2

1.49

1.99

SQLE

2.86

2.5

IDI1

7.23

4.15

DISCUSSION

Successful radiosensitisation has significant potential to provide
improved prognosis in PC patients. Increasing radiotherapy effectiveness would greatly improve outcome for patients with locally
advanced disease, as a greater proportion of patients would be
successfully downstaged to resectable disease, thereby improving

Abbreviation: qRT-PCR ¼ quantitative real-time PCR.
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Figure 4. Effect of ZOL on radiation therapy of subcutaneous mouse
allograft tumours. Immune-competent mice were injected s.c. with
UN-KPC-961 cells in two areas – one to be irradiated and one as
unirradiated control. Half of the mice were given ZOL (2 mg kg ÿ 1) 1–2 h
before the first radiation dose. Each mouse was aligned to its CT scan
by ExacTrac and then stereotactically irradiated on 5 consecutive days
with 7 Gy fractions. Waterfall plot showing percentage change in
tumour volume at day 17 as observed by caliper measurement of
tumours for all mouse tumours examined in the study. Similar results
were observed with volume measured by CT imaging. Median of each
treatment group is marked with ‘m’.

their 5-year survival rate from 8.6 to 21.5% and providing them with
access to the only PC therapy with reasonable curative potential
(SEER; National Cancer Institute, 2011). This study determined
pathways associated with PC radioresistance through comparison of
natural and radioselected radioresistant cell lines with their
differentially radiosensitive counterparts. These methods allow for
the discovery of genes common to both PC cell lines with inherent
radioresistance and the radioresistant subpopulations of PC cell lines
with relative radiosensitivity, providing comprehensive insight into
genes associated with PC’s evasion of IR-induced cell death.
Such methods for isolating radioresistant subpopulations from
cell lines have been previously reported using breast (Li et al, 2001),
oesophageal (Fukuda et al, 2004), and lung cancer (Xu et al, 2008;
Lee et al, 2010) cell lines. Unbiased analysis of radioresistance in
PC has been attempted only once before (Ogawa et al, 2006), with
some major differences with our study. Ogawa et al used high-dose
fractions and high total dose (10 Gy fractions with 14-day recovery
period between each fraction for total dose 150–180 Gy), whereas
we used 10 fractions of 2 Gy in a 2-week period (total dose 20 Gy).
Ogawa et al used a different microarray platform and used only
one cell line in common with our study, Panc-1, but were unable to
establish a radioresistant subline from it. These differences may
explain why none of the differentially expressed genes were
common between their study and ours. Ogawa et al found 73
upregulated genes common to radioresistant sublines, including
the growth factor amphiregulin, and genes associated with cell
proliferation (MAPKAPK2), intracellular calcium signalling (regucalcin) and disruption of vascularisation (angiopoietin 2).
Downregulated genes included genes associated with apoptosis
(caspase 8) and others. Encouragingly, siRNA screens are now
being used to identify radiosensitisation targets, such as PPP2R1A,
a scaffolding protein of phosphatase 2A (Wei et al, 2013). Of the 69
confirmed hits from this screen done in MiaPaCa-2 cells, suspected
(Chk1, ATR, MCL1) and novel genes (PLA2G4B, GPR2, MTMR3,
RAD9A, KLC2L, KIFAP3, KLF3, DVL2, LZTR1, SIAH2, PLCD1)
were identified as targets for radiosensitisation. More cell lines
require testing with these screens to capture the heterogeneities in
PC radioresponse.
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Such unbiased studies are necessary as previous attempts at
determining the causes of PC radioresistance relied primarily on
specific pathways related to apoptosis, cell survival, and cell cycle
progression while overlooking other pathways and cellular
processes that are considered to likely result in increased radioresistance, such as DNA damage recognition and repair (DiBiase
et al, 1999; Satyamoorthy et al, 2000; Macaulay et al, 2001; Munshi
et al, 2004; Kim et al, 2007; Hui et al, 2009; Wang et al, 2009;
Romano et al, 2010). In addition, despite the few pathways
currently implicated in PC radioresistance, none has yet been
effectively targeted to elicit therapeutic radiosensitisation clinically.
The results of this study indicate the importance of cholesterol
and fatty acid biosynthesis in PC radiation resistance. Such
implication has only been indicated once before in a directed study
showing that fatty acid synthase (FASN) is associated with PC
radioresponse (Yang et al, 2011). Importantly, increased expression
of FASN was found to be strongly associated with both natural and
radioselected radioresistance in our study as well, validating both
our methods as well as the observations of this previous study. We
specifically found that FDPS, an important branchpoint enzyme of
the cholesterol synthesis pathway, is directly involved in radioresistance (Figure 2C and D). Moreover, FDPS was expressed in all
PC cell lines tested (Figure 2B) and is overexpressed in human PC
tissues (Figure 2E–G). Low-to-moderate expression in normal
pancreas as observed in our study has also been reported earlier
(Romanelli et al, 2009). Although FDPS has been seen to be
overexpressed in multiple solid cancers by gene expression
microarray (Pilarsky et al, 2004), to our knowledge, this is the
first report to determine FDPS protein levels in human cancer
tissues. Although elucidation of the molecular mechanisms
underlying the association of FDPS, FASN, as well as the nine
other radioresistance-associated genes, with PC radioresistance has
not yet been undertaken in this or previous works, previous studies
indicating the necessity for cholesterol biosynthesis in the
membrane association and activity of both mutant and wild-type
KRAS in PC may explain our observations (Ura et al, 1994). To
this point, ZOL and cholesterol-lowering statins (that is, HMGCoA reductase inhibitors) have been shown to decrease Ras
prenylation or Ras protein levels in cells with mutant Ras (Tassone
et al, 2003; Marten et al, 2007; Wasko et al, 2011).
Our studies indicate the potential of targeting cholesterol
biosynthesis for radiosensitisation of PC through the successful
synergy of siRNA knockdown of FDPS and IR in vitro, and ZOL
and IR in vitro and in vivo. Currently, ZOL, a potent inhibitor of
FDPS, is used in the treatment of patients with breast and prostate
cancers that have metastasised to the bone, to prevent treatmentassociated bone loss in breast cancer, as well as to slow the
progression of osteoporosis (Brufsky et al, 2007; Gnant et al, 2007).
ZOL has also undergone clinical trials as an adjuvant to standard of
care for breast cancer, showing mixed efficacy results (Brufsky
et al, 2007; Gnant et al, 2007; Coleman et al, 2011). ZOL has been
seen to radiosensitise fibrosarcoma (Koto et al, 2013), osteosarcoma (Ryu et al, 2010), oesophageal squamous cell carcinoma (You
et al, 2014), and breast cancer cells (Ural et al, 2006) in preclinical
studies. Importantly, ZOL has recently undergone preclinical study
as a chemosensitiser for PC, specifically as an add-on therapy to
enhance the efficacy of gemcitabine, with promising results (Zhao
et al, 2012). A phase II clinical study of ZOL with gemcitabine in
advanced PC patients (n ¼ 35 enroled) showed the combination to
be well-tolerated, although final results have not been published
(ASCO 2006 abstract; Cov et al, 2006). An additional phase I trial
(n ¼ 15) for neoadjuvant ZOL treatment for patients with
resectable PC also was well tolerated (Sanford et al, 2013). To
date, however, no study has examined ZOL specifically as a
radiosensitiser in PC. Our results indicate that ZOL treatment can
significantly radiosensitise PC cell lines in vitro (Figure 3). The ER
of 1.3–1.5 is comparable with that reported for known
www.bjcancer.com | DOI:10.1038/bjc.2014.385
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radiosensitisers, such as gemcitabine (Pauwels et al, 2005) and
cisplatin (Skov and MacPhail, 1991), and for other reported
radiosensitisers, such as dual prenyl transferase inhibitors (Brunner
et al, 2005), the HIV protease inhibitor nelfinavir (Kimple et al,
2010), and Chk1 and PARP inhibitors (Vance et al, 2011).
ZOL treatment also provided a trend towards radiosensitisation
of allograft tumours of a radioresistant murine cell line derived
from a genetically engineered KPC mouse tumour (Figure 4). The
dose of ZOL used (2 mg kg ÿ 1) is equivalent to a 10 mg human
dose calculated based on body surface area (Reagan-Shaw et al,
2008), and it should be noted that the standard clinical dose of
ZOL, administered as an infusion every 3–4 weeks in the treatment
of cancer-induced bone disease, is 4 mg, which yields a peak
plasma concentration (Cmax) of 1–2 mM (Rogers and Holen, 2011).
This dose was chosen because it is within the range of ZOL used in
clinical trials (4–16 mg) and because it is well below the highest
reported non-lethal single dose (10 mg kg ÿ 1) in mice (Zometa
package insert, 2006). Possible reasons for not reaching significance in the in vivo studies could be single dose administration of
ZOL to more accurately reflect clinical dosing, use of a highly
radioresistant cell line, or a sample size of mice too small to reach
significance. Further study is needed to determine whether
multiple doses of ZOL may enhance radiosensitisation.
Using a clinical CT scanner, clinical treatment planning
software, and linear accelerator, we were able to accurately and
precisely irradiate subcutaneous tumours at high doses without
shielding. Although most preclinical studies use small-dose
fractions (3–10 fractions of 1–2 Gy; Morgan et al, 2008; Kimple
et al, 2010; Wei et al, 2013), we were able to deliver high-dose
fractions (five fractions of 7 Gy), which are being investigated in
stereotactic hypofractionated regimens for PC at UNMC and other
institutions. By using immune-competent mice in our study, we
better modeled the effects of radiation on the immune system,
clearance of radiated cancer cells by the immune system, and
possible immunogenicity of radiated tumours (abscopal effect).
This also provides for added anti-tumour effects of ZOL from a
competent immune system, such as through activation of gamma
delta (gd) T cells (Marten et al, 2007), repolarisation of
macrophages (Coscia et al, 2010; Rogers and Holen, 2011), and
impairment of myeloid-derived suppressor cells (Porembka et al,
2012).
Despite the novelty and positive results of this work, several
pitfalls remain. Currently, the only in vivo model available for PC
radiation research consists of subcutaneous transplantation that
has proven a poor indicator of clinical efficacy for both chemo- and
radiotherapy. In addition, only two cell lines and two cell line
derivatives were utilised in the gene expression microarray
profiling in this study (although more were used to check FDPS
expression and to test ZOL), potentiating that our results may not
remain consistent across all PC cells lines or in the complexities of
PC patients. It is further important to note that the radioresisant
phenotype was diminished beyond 18 passages in the absence of
continued radiation exposure. Also, we are yet to determine
whether ZOL can radiosensitise normal organs involved in
radiation toxicity, such as small intestine. Biochemical tests are
also needed to determine tumour uptake of ZOL, as bisphosphonates accumulate highly in bones. However, this study
describes comprehensive pathway analysis from the context of
PC radiation resistance and opens avenues for future studies both
in PC as well as in other cancers with low radiation efficacy. For
example, several interesting upregulated genes in our microarray
could be investigated for their role in radioresistance, including the
chemokine CCL2 and the splicing factor SFPQ (PSF), which is
associated with DNA repair and RNA biogenesis and mediates
radioresistance of HeLa cells (Ha et al, 2011). Downregulated genes
in our microarray, such as the pro-apoptotic BNIP3 and galectin-3
(LGALS3), could prove to be important radioresponse genes.
www.bjcancer.com | DOI:10.1038/bjc.2014.385
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On the basis of our results, several future studies are warranted.
Microarray analysis and correlation of gene expression with
radioresistance, both natural and radioselected, should be undertaken in a greater number of cell lines to determine the universality
of the identified genes across all PC. This approach could also be
used to compare the gene expression profiles of radiation
responder vs non-responder human tumours. For example,
unbiased analysis of tumour samples taken pre-irradiation could
be correlated with treatment response. In addition, ZOL should be
further studied as a radiosensitiser using either spontaneous
genetically engineered mouse models or directly in phase I trials.
Further, unbiased studies such as this should be undertaken in
other cancers such as renal cell carcinoma and melanoma, in which
radiotherapy has a significant role in patient treatment but lacks
general efficacy, to determine novel pathways and targets for
radioresistance.
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